Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDegLira versus insulin glargine for long-term glycaemic control in type 2 diabetes
2014-005639-15Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM) comparing IDegLira arm with Insulin glargine arm (2 arms). Primary endpoint: Time to inadequate glycaemic control and need for treatment intensification. Started Sep 2015; status: completed.
02
Drugs
insulin degludec + liraglutideinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-005639-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005639-15.